RecruitingNot Applicable

Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes

United States800 participantsStarted 2025-08-06

Plain-language summary

A pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies using an EHR embedded clinical decision support tool.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Clinical cohort inclusion exclusion criteria: Inclusion Criteria: * Patients with diagnosis of Type 2 diabetes and High WATCH DM score. * Echocardiogram available in last 6-months. Exclusion Criteria: * History of HF * Not eligible for prescription of new GLP-1RA or SGLT2i or ns-MRA Corresponding providers to patients identified by the above inclusion exclusion criteria will be included in the clinical trial of the decision support tool.

What they're measuring

Frequency of prescription of SGLT-2i medication at outpatient clinic visits over 3 months follow-up

Timeframe: 3-month follow-up

Frequency of prescription of SGLT-2i medication at outpatient clinic visits over 6 months follow-up

Timeframe: 3-month follow-up

Trial details

NCT IDNCT06593314

SponsorUniversity of Texas Southwestern Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-09-15

Contact for this trial

Ambarish Pandey, MD

617-869-8957 Ambarish.Pandey@UTSouthwestern.edu

View on ClinicalTrials.gov More Heart Failure trials